MicroRNA-29a Inhibits Glioblastoma Stem Cells and Tumor Growth by Regulating the PDGF Pathway

Overview

Journal J Neurooncol

Publisher Springer

Date 2019 Sep 5

PMID 31482267

Citations 20

Authors

Yanzhi Yang

Samantha Dodbele

Thomas Park

Rainer Glass

Krishna Bhat

Erik P Sulman

Ying Zhang

Roger Abounader

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: microRNAs are small noncoding RNAs that play important roles in cancer regulation. In this study, we investigated the expression, functional effects and mechanisms of action of microRNA-29a (miR-29a) in glioblastoma (GBM).

Methods: miR-29a expression levels in GBM cells, stem cells (GSCs) and human tumors as well as normal astrocytes and normal brain were measured by quantitative PCR. miR-29a targets were uncovered by target prediction algorithms, and verified by immunoblotting and 3' UTR reporter assays. The effects of miR-29a on cell proliferation, death, migration and invasion were assessed with cell counting, Annexin V-PE/7AAD flow cytometry, scratch assay and transwell assay, respectively. Orthotopic xenografts were used to determine the effects of miR-29a on tumor growth.

Results: Mir-29a was downregulated in human GBM specimens, GSCs and GBM cell lines. Exogenous expression of miR-29a inhibited GSC and GBM cell growth and induced apoptosis. miR-29a also inhibited GBM cell migration and invasion. PDGFC and PDGFA were uncovered and validated as direct targets of miR-29a in GBM. miR-29a downregulated PDGFC and PDGFA expressions at the transcriptional and translational levels. PDGFC and PDGFA expressions in GBM tumors, GSCs, and GBM established cell lines were higher than in normal brain and human astrocytes. Mir-29a expression inhibited orthotopic GBM xenograft growth.

Conclusions: miR-29a is a tumor suppressor miRNA in GBM, where it inhibits cancer stem cells and tumor growth by regulating the PDGF pathway.

Citing Articles

Expression of some circulating microRNAs as predictive biomarkers for prognosis and treatment response in glioblastoma.

Ali E, Ahmed M, Shawki M, El Arab L, Khalifa M, Swellam M Sci Rep. 2025; 15(1):1933.

PMID: 39809835 PMC: 11733229. DOI: 10.1038/s41598-024-83800-x.

Use of microRNAs as Diagnostic, Prognostic, and Therapeutic Tools for Glioblastoma.

Valle-Garcia D, la Cruz V, Flores I, Salazar A, Pineda B, Meza-Sosa K Int J Mol Sci. 2024; 25(5).

PMID: 38473710 PMC: 10931459. DOI: 10.3390/ijms25052464.

HSV1 microRNAs in glioblastoma development: an in silico study.

Shadbad M, Hemmat N, Abdoli Shadbad M, Brunetti O, Silvestris N, Baradaran B Sci Rep. 2024; 14(1):27.

PMID: 38167429 PMC: 10761845. DOI: 10.1038/s41598-023-45249-2.

miR-3174 Is a New Tumor Suppressor MicroRNA That Inhibits Several Tumor-Promoting Genes in Glioblastoma.

Hanif F, Zhang Y, Dube C, Gibert Jr M, Saha S, Hudson K Int J Mol Sci. 2023; 24(11).

PMID: 37298284 PMC: 10253284. DOI: 10.3390/ijms24119326.

Strategies, considerations, and recent advancements in the development of liquid biopsy for glioblastoma: a step towards individualized medicine in glioblastoma.

Bauman M, Bouchal S, Monie D, Aibaidula A, Singh R, Parney I Neurosurg Focus. 2022; 53(6):E14.

PMID: 36455271 PMC: 9879623. DOI: 10.3171/2022.9.FOCUS22430.

References

Xi Z, Wang P, Xue Y, Shang C, Liu X, Ma J . Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6. Oncotarget. 2017; 8(15):24949-24963. PMC: 5421901. DOI: 10.18632/oncotarget.15327. View

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Di Rocco F, Carroll R, Zhang J, Black P . Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery. 1998; 42(2):341-6. DOI: 10.1097/00006123-199802000-00080. View

Martinho O, Longatto-Filho A, Lambros M, Martins A, Pinheiro C, Silva A . Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Br J Cancer. 2009; 101(6):973-82. PMC: 2743351. DOI: 10.1038/sj.bjc.6605225. View

Assanah M, Lochhead R, Ogden A, Bruce J, Goldman J, Canoll P . Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci. 2006; 26(25):6781-90. PMC: 6673823. DOI: 10.1523/JNEUROSCI.0514-06.2006. View

Heldin C, Westermark B . Platelet-derived growth factors: a family of isoforms that bind to two distinct receptors. Br Med Bull. 1989; 45(2):453-64. DOI: 10.1093/oxfordjournals.bmb.a072334. View

Godlewski J, Nowicki M, Bronisz A, Nuovo G, Palatini J, De Lay M . MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell. 2010; 37(5):620-32. PMC: 3125113. DOI: 10.1016/j.molcel.2010.02.018. View

Yeh H, Silos-Santiago I, Wang Y, George R, Snider W, Deuel T . Developmental expression of the platelet-derived growth factor alpha-receptor gene in mammalian central nervous system. Proc Natl Acad Sci U S A. 1993; 90(5):1952-6. PMC: 45998. DOI: 10.1073/pnas.90.5.1952. View

Li Y, Guessous F, Zhang Y, diPierro C, Kefas B, Johnson E . MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009; 69(19):7569-76. PMC: 2756313. DOI: 10.1158/0008-5472.CAN-09-0529. View

10.

Godlewski J, Nowicki M, Bronisz A, Williams S, Otsuki A, Nuovo G . Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 2008; 68(22):9125-30. DOI: 10.1158/0008-5472.CAN-08-2629. View

11.

Heidaran M, PIERCE J, Yu J, Lombardi D, Artrip J, Fleming T . Role of alpha beta receptor heterodimer formation in beta platelet-derived growth factor (PDGF) receptor activation by PDGF-AB. J Biol Chem. 1991; 266(30):20232-7. View

12.

Li Y, Guessous F, Kwon S, Kumar M, Ibidapo O, Fuller L . PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Res. 2008; 68(6):1723-31. PMC: 3813002. DOI: 10.1158/0008-5472.CAN-07-1963. View

13.

Xu H, Sun J, Shi C, Sun C, Yu L, Wen Y . miR-29s inhibit the malignant behavior of U87MG glioblastoma cell line by targeting DNMT3A and 3B. Neurosci Lett. 2015; 590:40-6. DOI: 10.1016/j.neulet.2015.01.060. View

14.

Nister M, Libermann T, Betsholtz C, Pettersson M, Claesson-Welsh L, Heldin C . Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res. 1988; 48(14):3910-8. View

15.

Guessous F, Alvarado-Velez M, Marcinkiewicz L, Zhang Y, Kim J, Heister S . Oncogenic effects of miR-10b in glioblastoma stem cells. J Neurooncol. 2013; 112(2):153-63. PMC: 3609924. DOI: 10.1007/s11060-013-1047-0. View

16.

Ligon K, Kesari S, Kitada M, Sun T, Arnett H, Alberta J . Development of NG2 neural progenitor cells requires Olig gene function. Proc Natl Acad Sci U S A. 2006; 103(20):7853-8. PMC: 1472534. DOI: 10.1073/pnas.0511001103. View

17.

Li Y, Guessous F, Johnson E, Eberhart C, Li X, Shu Q . Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Lab Invest. 2007; 88(2):98-111. DOI: 10.1038/labinvest.3700702. View

18.

Shi C, Ren L, Sun C, Yu L, Bian X, Zhou X . miR-29a/b/c function as invasion suppressors for gliomas by targeting CDC42 and predict the prognosis of patients. Br J Cancer. 2017; 117(7):1036-1047. PMC: 5625669. DOI: 10.1038/bjc.2017.255. View

19.

Singh S, Hawkins C, Clarke I, Squire J, Bayani J, Hide T . Identification of human brain tumour initiating cells. Nature. 2004; 432(7015):396-401. DOI: 10.1038/nature03128. View

20.

Heldin C, Westermark B . Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999; 79(4):1283-316. DOI: 10.1152/physrev.1999.79.4.1283. View